Increased strength of erythrocyte aggregates in blood of patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 15, Issue 5, 2009, Pages 707-713

  Maharshak, Nitsan ^a   Arbel, Yaron ^a   Shapira, Itzhak ^a   Berliner, Shlomo ^a   Ben Ami, Ronen ^a   Yedgar, Saul ^b   Barshtein, Gershon ^b   Dotan, Iris ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

Acute phase response; Erythrocyte aggregation

Indexed keywords

AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STEROID;

ADULT; AREA UNDER THE CURVE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; ERYTHROCYTE AGGREGATION; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; SHEAR STRESS; ULCERATIVE COLITIS;

ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; ERYTHROCYTE AGGREGATION; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 67650337057     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20838     Document Type: Article

References (51)

1. Soutani M, Suzuki Y, Tateishi N, et al. Quantitative evaluation of flow dynamics of erythrocytes in microvessels: influence of erythrocyte aggregation. Am J Physiol. 1995;268:H1959-H1965.
2. Bishop JJ, Nance PR, Popel AS, et al. Effect of erythrocyte aggregation on velocity profiles in venules. Am J Physiol Heart Circ Physiol. 2001;280:H222-H236.
3. Cabel M, Meiselman HJ, Popel AS et al. Contribution of red blood cell aggregation to venous vascular resistance in skeletal muscle. Am J Physiol. 1997;272:H1020-H1032.
4. Bishop JJ, Nance PR, Popel AS, et al. Relationship between erythrocyte aggregate size and flow rate in skeletal muscle venules. Am J Physiol Heart Circ Physiol. 2004;286:H113-H120.
5. Yalcin O, Uyuklu M, Armstrong JY, et al. Graded alterations of RBC aggregation influence in vivo blood flow resistance. Am J Physiol Heart Circ Physiol. 2004;287:H2644-H2650.
6. Kim S, Popel AS, Intaglietta M, et al. Aggregate formation of erythrocytes in postcapillary venules. Am J Physiol Heart Circ Physiol. 2005; 288:H584-H590.
7. Mchedlishvili G, Gobejishvili L, Mamaladze A, et al. Microcirculatory stasis induced by hemorheological disorders: further evidence. Microcirculation. 1999;6:97-106.
8. Mchedlishvili G, Varazashvili M, Gobejishvili L. Local RBC aggregation disturbing blood fluidity and causing stasis in microvessels. Clin Hemorheol Microcirc. 2002;26:99-106.
9. Schmid-Schonbein H. Blood rheology and physiology of microcirculation. Ric Clin Lab. 1981;11(suppl 1):13-33.
10. 2-permeable tube: effects of erythrocyte aggregation. Am J Physiol Heart Circ Physiol. 2001; 281:H448-H456.
11. Tateishi N, Suzuki Y, Shirai M, et al. Reduced oxygen release from erythrocytes by the acceleration-induced flow shift, observed in an oxygen-permeable narrow tube. J. Biomech. 2002;35:1241-1251.
12. Baskurt OK, Yalcin O, Ozdem S, et al. Modulation of endothelial nitric oxide synthase expression by red blood cell aggregation. Am J Physiol Heart Circ Physiol. 2004;286:H222-H229.
13. Kim S, Popel AS, Intaglietta M, et al. Effect of erythrocyte aggregation at normal human levels on functional capillary density in rat spinotrapezius muscle. Am J Physiol Heart Circ Physiol. 2006;290:H941-H947.
14. Hatoum OA, Binion DG, Gutterman DD. Paradox of simultaneous intestinal ischaemia and hyperaemia in inflammatory bowel disease. Eur J Clin Invest. 2005;35:599-609.
15. Hatoum OA, Binion DG, Otterson MF, et al.: Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology. 2003;125:58-69.
16. Foitzik T, Kruschewski M, Kroesen A, et al. Does microcirculation play a role in the pathogenesis of inflammatory bowel diseases? Answers from intravital microscopic studies in animal models. Int J Colorectal Dis. 1999;14:29-34.
17. Zilberman L, Rogowski O, Rozenblat M, et al. Inflammation-related erythrocyte aggregation in patients with inflammatory bowel disease. Dig Dis Sci. 2005;50:677-683.
18. Novacek G, Vogelsang H, Genser D, et al. Changes in blood rheology caused by Crohn's disease. Eur J Gastroenterol Hepatol. 1996;8:1089-1093.
19. Hayakawa M, Kuzuya F. Effects of ticlopidine on erythrocyte aggregation in thrombotic-disorders. Angiology. 1991;42:747-753.
20. Orringer EP, Casella JF, Ataga KI, et al. Purified potoxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA. 2001;286:2152-2153.
21. El Bouhmadi A, Laffargue F, Raspal N, et al. 100 mg acetylsalicylic acid acutely decreases red cell aggregation in women taking oral contraceptives. Clin Hemorheol Microcirc. 2000;22:99-106.
22. Banyai S, Banyai M, Falger J, et al. Atorvastatin improves blood rheology in patients with familial hypercholosterolemia (FH) on long term LDL apheresis treatment. Atherosclerosis. 2001;159:513-519.
23. Dujovne CA, Harris WS, Altman R, et al. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am J Cardiol. 2000;85:350-353.
24. Suckfull M. Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Lancet. 2002;360:1811-1817.
25. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 1979;77:843-846.
26. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
27. International committee for standardization in hematology. Recommendation for measurement of erythrocyte sedimentation rate of human blood. Am J Clin Pathol. 1977;68:505-507.
28. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol Basel. 1957;17:237-246.
29. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136-2141.
30. Ben Ami R, Barshtein G, Zeltser D, et al. Parameters of red blood cell aggregation as correlates of the inflammatory state. Am J Physiol Heart Circ Physiol. 2001;280:H1982-H1988.
31. Adar T, Ben-Ami R, Elstein D, et al. Aggregation of red blood cells in patients with Gaucher disease. Br J Haematol. 2006;134:432-437.
32. Chen S, Gavish B, Zhang S, et al. Monitoring of erythrocyte aggregate morphology under flow by computerized image analysis. Biorheology. 1995;32:487-496.
33. Chen S, Gavish B, Barshtein G, et al. Red blood cell aggregability is enhanced by physiological levels of hydrostatic pressure. Biochim Biophys Acta. 1994;1192:247-252.
34. Ben Ami R, Barshtein G, Mardi T, et al. A synergistic effect of albumin and fibrinogen on immunoglobulin-induced red blood cell aggregation. Am J Physiol Heart Circ Physiol. 2003;285:H2663-H2669.
35. Schechner V, Ben-Ami R, Hershcovici T, et al. Plasma dependent reduction in red blood cell aggregation after dextran sulfate low-density lipoprotein apheresis - implications for rheological studies. Ther Apher Dial. 2005;9:379-384.
36. Samocha-Bonet D, Ben-Ami R, Shapira I, et al. Flow-resistant red blood cell aggregaoon in morbid obesity. Int J Obes Relat Metab Disord. 2004;28:1528-1534.
37. Conroy CA, Cattell R. Infliximab treatment for Crohn's disease. Postgrad Med J. 2001;77:436-440.
38. Fabry TL. Mechanism of erythrocyte aggregation and sedimentation. Blood. 1987;70:1572-1576.
39. Maresca G, Di Blasio A, Marchioli R, et al. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol. 1999;19:1368-1377.
40. Forconi S, Turchetti V, Cappelli R, et al. Haemorheological disturbances and possibility of their correction in cerebrovascular diseases. J Mal Vasc. 1999;24:110-116.
41. Ehrly AM. Erythrocyte aggregation in clinical medicine. Klin Wochenschr. 1986;64:1081-1084.
42. Zeltser D, Serrov J, Mardi T, et al. Serum lipids as minor determinants of the degree of erythrocyte adhesiveness/aggregation in the peripheral blood of individuals with row grade inflammation and moderately increased serum lipids. Clin Hemorheol Microcirc. 2004;31:161-167.
43. Contreras T, Vaya A, Palanca S, et al. Influence of plasmatic lipids on the hemorheological profile in healthy adults. Clin Hemorheol Microcirc. 2004;30:423-425.
44. Pribush A, Zilberman-Kravits D, Meyerstein N. The mechanism of the dextran-induced red blood cell aggregation. Eur Biophys J. 2007;36:85-94.
45. Weng X, Cloutier G, Beaulieu R, et al. Influence of acute-phase proteins on erythrocyte aggregation. Am J Physiol. 1996;271:H2346-H2352.
46. Weng X, Roederer GO, Beaulieu R, et al. Contribution of acute-phase proteins and cardiovascular risk factors to erythrocyte aggregation in normolipidemic and hyperlipidemic individuals. Thromb Haemost. 1998;80:903-908.
47. Imaizumi Y, Shiga T. Effect of immunoglobulins and IgG-fragments on the human erythrocyte aggregation, studied by rheoscope combined with image analyzer. Biorheology. 1983;20:569-577.
48. Ben Assayag E, Bornstein NM, Shapira I, et al. Inflammation sensitive proteins and erythrocyte aggregation in atherothrombosis. Int J Cardiol. 2005;98:271-276.
49. Schechner V, Shapira I, Berliner S, et al. Significant dominance of fibrinogen over -immunoglobulins, C-reactive protein, cholesterol and triglycerides in maintaining increased red blood cell adhesiveness/ aggregation: a model in hypercholaesterolemic patients. Eur J Clin Invest. 2003;33:955-961.
50. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006;130:2060-2073.
51. Danese S. Inflammation and the mucosal microcirculation in inflammatory bowel disease: ebb and flow. Curr Opin Gastroenterol. 2007;23: 384-389.